Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity

Exclusion Criteria

• •1. Willingness and ability to sign an informed consent
• •2. HBV nucleos(t)ides and/or interferon exposure within 24 weeks of study medication dosing
• •3. HIV and other immune compromising condition (e.g. cancer with the exception of non-invasive cutaneous malignancy, autoimmune condition) or therapy (i.e. systemic steroids, chemotherapy)
• •4. HCV co-infected
• •5. Cirrhosis (defined by biopsy criteria or as \>18.4 kilopascal (kPa) by transient elastography)
• •6. Creatinine Clearance \<60 ml/min
• •7. Baseline hemoglobin \<130 g/L in males and \<120 g/L in females
• •8. Unwilling or unable to use contraception (unless confirmed surgical sterilization)
• •9. Pregnancy confirmed by blood test